

Special Issue

New Perspectives on Chronic Kidney Disease

Message from the Guest Editor

Chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide. Early detection plays a critical role in preventing the onset of kidney failure. Physicians assess patients for indicators of renal disease and perform a range of diagnostic tests to evaluate kidney function, including measurements such as serum creatinine level, cystatin C, blood urea nitrogen, glomerular filtration rate (eGFR), electrolyte levels, and red blood cell count, as well as urinalysis. On occasion, a biopsy of kidney tissue may be required for accurate diagnosis. To date, these tests have represented the standards for the diagnostics of kidney diseases. However, new technologies offer promising new ways to diagnose and prognose kidney diseases. Biomarkers other than plasma creatinine and the glomerular filtration rate are becoming crucial for the diagnosis and assessment of a patient's condition. New diagnostic methods play a significant role in diagnosis and provide greater treatment options.

This Special Issue aims to present recent advances in chronic kidney disease.

Guest Editor

Dr. Ewelina Młynarska

Department of Nephrocardiology, Medical University of Lodz, ul. Żeromskiego 113, 90-549 Lodz, Poland

Deadline for manuscript submissions

closed (30 November 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/203818

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).